PTPRO is a therapeutic target and correlated with immune infiltrates in pancreatic cancer

Xuben Hou 1, Jintong Du 2,* and Hao Fang 1,*

1 Department of Medicinal Chemistry and Key Laboratory of Chemical Biology of Natural Products (MOE), Cheeloo College of Medicine, School of Pharmaceutical Science, Shandong University, Jinan, Shandong, 250012, China
2 Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, 250117, China

Supplementary Materials
Table S1. Relation between PTPRO expression and patient prognosis of different cancer in Prognoscan database (Cox $P$-value < 0.05).

| Cancer type       | Database      | Endpoint | N  | Cox $P$-value | ln(HR) | HR [95% CI$_{low}$ - CI$_{upp}$] |
|-------------------|---------------|----------|----|---------------|--------|----------------------------------|
| Blood cancer      | GSE4475       | OS       | 158| 0.000024      | 0.71   | 2.02 [1.46 - 2.81]               |
| Blood cancer      | GSE12417-GPL570| OS       | 79 | 0.010492      | -2.29  | 0.10 [0.02 - 0.59]               |
| Blood cancer      | GSE5122       | OS       | 58 | 0.011185      | 0.48   | 1.62 [1.12 - 2.34]               |
| Brain cancer      | GSE16581      | OS       | 67 | 0.002598      | 2.46   | 11.72 [2.36 - 58.14]             |
| Breast cancer     | E-TABM-158    | DMFS     | 117| 0.008087      | 0.92   | 2.51 [1.27 - 4.98]               |
| Breast cancer     | GSE7849       | DFS      | 76 | 0.031508      | -0.59  | 0.56 [0.33 - 0.95]               |
| Breast cancer     | GSE9195       | RFS      | 77 | 0.044722      | 1.21   | 3.36 [1.03 - 10.97]              |
| Breast cancer     | GSE7390       | DMFS     | 198| 0.048062      | 0.34   | 1.41 [1.00 - 1.98]               |
| Colorectal cancer | GSE17537      | OS       | 55 | 0.018226      | -0.55  | 0.57 [0.36 - 0.91]               |
| Colorectal cancer | GSE17537      | DFS      | 55 | 0.026472      | -0.58  | 0.56 [0.34 - 0.93]               |
| Esophagus cancer  | GSE11595      | OS       | 34 | 0.040433      | 1.03   | 2.79 [1.05 - 7.44]               |
| Esophagus cancer  | GSE11595      | OS       | 34 | 0.040433      | 1.03   | 2.79 [1.05 - 7.44]               |
| Lung cancer       | GSE31210      | RFS      | 204| 0.004968      | 0.7    | 2.02 [1.24 - 3.29]               |
| Lung cancer       | GSE31210      | OS       | 204| 0.013116      | 0.83   | 2.30 [1.19 - 4.44]               |
| Lung cancer       | jacob-00182-MSK| OS       | 104| 0.037743      | -1.02  | 0.36 [0.14 - 0.94]               |
| Ovarian cancer    | GSE9891       | OS       | 278| 0.03363       | -0.27  | 0.76 [0.60 - 0.98]               |
| Soft tissue cancer| GSE30929      | DRFS     | 140| 0.021113      | -0.4   | 0.67 [0.48 - 0.94]               |
Figure S1. (A) Chemical structure of PTPRO inhibitor **GP03**. (B) Predicted binding mode of **GP03** against PTPRO. Molecular docking was performed using Autodock Vina. The unoccupied spaces were marked with red arrows.

Figure S2. Dose-dependent inhibition of **GP03** on proliferation of SW1990 cells.